ALFA Finder| Management target | Revenue 99.9% FY27 |
|---|
| Revenue growth | Revenue grew 21.8% YoY driven by pharma segment expansion. |
|---|---|
| Margins | Gross margins down 200 bps due to lower private label mix. |
| Demand visibility | Strong pharmacy demand; diagnostic segment plans for 2.5 lakh active plans. |
| Management confidence | Defensive regarding recent non-core capex plans and margin contraction. |
Growth
Revenue grew 21.8% YoY, though private label share dipped to 20% impacting profitability.
Outlook
Maintains guidance for 800 net new stores in FY27 despite putting non-core capex on hold.
Risks
Higher employee costs in Karnataka/Telangana and a failing franchise model with 52 store closures.
Last quarter's promises, checked
Delivered
- Guided 600+ net store additions FY26 → delivered 618 (= BEAT)
- Guided 9-10% SSSG → delivered 17.8% (= BEAT)
- Guided 5.7-5.8% EBITDA margin → delivered 5.8% (= BEAT)
Partly delivered
- Guided 800 net new stores FY27 → maintained target but put core capex on hold (= PARTIAL)
Missed
- Guided 20-30 bps PL share growth/qtr → delivered 20% total share vs 22% prev (= MISS)
- Guided 135.5% OCF/EBITDA ratio → delivered negative leverage (= MISS)
Earnings Call Transcript filed with NSE, NSE: MEDPLUS. Summary written with AI assistance from the document.
Medplus Health Services Ltd: key numbers
- Share price
- ₹625.80
- Market cap
- ₹7,519 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 35.6×Sector 54.5×
- Promoter holding
- 40.19%+0.00% QoQ
- FII holding
- 12.58%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Adverse Business Impact
Medplus subsidiary Optival Health received a two-day drug licence suspension for its Kothagudem store. Expected financial impact is Rs 0.44 lacs, and compliance measures are underway.
- Value
- ₹0.00 Cr
Medplus Health Services Adverse Business Impact
MedPlus stores in Karnataka face four-day drug licence suspensions. Expected financial impact is about Rs 4.06 lacs.
- Value
- ₹0.04 Cr
- Execution
- Four days
Medplus Health Services Capital Structure Change
MedPlus approved a buyback of 17.33 lakh shares at ₹750 each, up to ₹130 crore. The buyback equals about 1% of paid-up capital via open market.
- Value
- ₹130.0 Cr
Medplus Health Services Adverse Business Impact
MedPlus Health Services' subsidiary Optival Health Solutions had its drug licence suspended for five days for a Suryapet store. Expected financial impact is about Rs 1.32 lakh.
- Value
- ₹0.01 Cr
- Execution
- 05 days
Medplus Health Services Board Meeting Date
MedPlus Health Services scheduled a board meeting for 6 November 2026 to consider a share buy-back. The trading window for designated persons closes from 30 October 2026.
Medplus Health Services Capital Structure Change
ICICI Prudential Mutual Fund disclosed under Regulation 29(2) that it bought 24,35,693 Medplus shares, lifting its stake to 9.21%. The acquisition was made in the open market, not off-market.
- Promoter stake change
- +1.97%